Keytruda pembrolizumab: Phase II data

Top-line data from 23 evaluable patients with advanced or metastatic MCC who received

Read the full 138 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE